Nanosystems for simultaneous imaging and drug delivery to T cells
Journal Title: The AAPS Journal - Year 2007, Vol 9, Issue 2
Abstract
The T-cell response defines the pathogenesis of many common chronic disease states, including diabetes, rheumatoid arthritis, and transplant rejection. Therefore, a diagnostic strategy that visualizes this response can potentially lead to early therapeutic intervention, avoiding catastrophic organ failure or prolonged sickness. In addition, the means to deliver a drug dose to those cells in situ with the same specificity used to image those cells would provide for a powerful therapeutic alternative for many disease states involving T cells. In this report, we review emerging nanosystems that can be used for simultaneous tracking and drug delivery to those cells. Because of their versatility, these systems—which combine specific receptor targeting with an imaging agent and drug delivery—are suited to both basic science and applications, from developing therapeutic strategies for autoimmune and alloimmune diseases, to noninvasive tracking of pathogenic T-cell migration.
Authors and Affiliations
Tarke M. Fahmy, Peter M. Fong, Jason Park, Todd Constable, W. Mark Saltzman
Keywords
Related Articles
- EP ID EP681587
- DOI 10.1208/aapsj0902019
- Views 78
- Downloads 0
Bioequivalence studies for levothyroxine
The Food and Drug Administration (FDA) Guidance for Bioavailability and Bioequivalence Studies for Levothyroxine has been challenged by companies that manufacture brand-name products. Their contention is that the current...
Influence of Drug Properties and Formulation on In Vitro Drug Release and Biowaiver Regulation of Oral Extended Release Dosage Forms
Bioequivalence (BE) studies are often required to ensure therapeutic equivalence for major product and manufacturing changes. Waiver of a BE study (biowaiver) is highly desired for such changes. Current regulatory guidel...
Rapid in vivo oral screening in rats: Reliability, acceptance criteria, and filtering efficiency
The reliability and acceptance criteria of rapid oral exposure screening were evaluated by pharmacokinetic simulations and by comparing oral exposure of 100 proprietary compounds from 15 therapeutic programs obtained at...
Aggregation Kinetics for IgG1-Based Monoclonal Antibody Therapeutics
Monoclonal antibodies (mAbs) as a class of therapeutic molecules are finding an increasing demand in the biotechnology industry for the treatment of diseases like cancer and multiple sclerosis. A key challenge associated...
Comparative In Silico–In Vivo Evaluation of ASGP-R Ligands for Hepatic Targeting of Curcumin Gantrez Nanoparticles
The online version of this article (doi:10.1208/s12248-013-9474-6) contains supplementary material, which is available to authorized users.